| Mark W. Grinstaff | |
| Birth Date: | 23 May 1965 |
| Birth Place: | Texas |
| Fields: | Translational research Biomedical engineering Chemistry Material science |
| Work Institutions: | Duke University Boston University National Institutes of Health |
| Alma Mater: | Occidental College University of Illinois at Urbana–Champaign |
Mark W. Grinstaff (born May 23, 1965) is the William Fairfield Warren Distinguished Professor and a Professor of Biomedical Engineering, Chemistry, Materials Science and Engineering and Medicine, at Boston University, Director of the National Institutes of Health's T32 Program in Translational Research in Biomaterials and Director of Nanotechnology Innovation Center. Grinstaff is an avid mentor and teacher who is always asking questions. In the laboratory, he has developed new paradigms for translating rigorous, academic work, which promotes intellectual progress, economic growth, and improved clinical outcomes. His career is marked by exploration of new areas and reinvention, and his discoveries have and continue to significantly impact multiple research areas. He is a co-founder of several companies and a co-inventor of several regulatory approved drug and device products used in the clinic today.
Grinstaff was born on May 23, 1965, in Texas. [1] [2] He attended Redlands High School in Redlands, California, and was an Eagle Scout and Vigil member of the Order of the Arrow, Boy Scouts of America. Grinstaff completed his undergraduate studies at Occidental College. During his first year at Oxy, he worked at the hummingbird section of a museum while simultaneously studying the kinetics of Friedel-Crafts chloromethylation reactions in the laboratory of Franklin DeHaan. He later worked as a chemistry teaching assistant. During his junior year at Oxy, he decided to pursue chemistry over medicine.[2] He obtained his Chemistry degree in 1987.[3]
In 1992, Grinstaff earned his doctorate from the University of Illinois at Urbana–Champaign,[3] under the mentorship of Kenneth S. Suslick. While at UIUC he studied sonochemistry and reported one of the first synthetic methods to metal nanoparticles. His thesis focused on the use of sound waves to make amorphous iron and protein-nanoparticles and microspheres. For his postdoctoral work, he joined Harry B. Gray's laboratory at the California Institute of Technology where he conducted research on electron transfer chemistry in proteins and the mechanism of alkane hydroxylation using iron porphyrins and oxygen.[1]
Grinstaff served as a faculty member at Duke University from 1996 to 2002. During this time, he was part of the Pharmacology Training Grant Program and the Center for Cellular and Biosurface Engineering. He was also an assistant professor of ophthalmology at Duke University Hospital (1999-2002).
In 2003, Grinstaff relocated to Boston University as part of the recruitment activities associated with the Whitaker Foundation Leadership Award granted to the Department of Biomedical Engineering. He joined Boston University as an associate professor with joint appointments in the Boston University College of Engineering and Boston University College of Arts and Sciences, and subsequently with an appointment at Boston University School of Medicine. In 2004, he served as a faculty member of the Boston University Center for Nanoscience and Nanobiotechnology, becoming the director in 2014.[2]
In 2015, Grinstaff obtained a grant from Bill & Melinda Gates Foundation to develop the self-lubricating condom.[4] Under his watch, four successful biotech companies have emerged: AcuityBio, Affinergy, Articular Biosciences and HyperBranch Medical Technology.[5] Additionally, Grinstaff co-founded five companies and is the inventor of four products by Adherus Surgical Sealants and OcuSeal.[6]
Grinstaff serves on an advisory board of the Syracuse Biomaterials Institute.[7]
In 2001, Grinstaff wrote Proceedings from the Workshop on Nanoscience for the Soldier of which he was also principal investigator.[8]